ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

XENE vs OGN // GROSS PROFIT MARGIN

Xenon Pharmaceuticals Inc. (NASDAQ) VS. Organon & Co. (NYSE) • 15-METRIC TALLY: XENE 2 — OGN 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XENE VS. OGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC XENE OGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 53.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 24.90% -59.90 OGN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -7.70% 14.83% -22.53 OGN /fcf-yield <GO>
Operating Margin -36.70% — — TIE /operating-margins <GO>
Net Profit Margin -34.00% 3.00% -37.00 OGN /net-margins <GO>
Revenue Growth (YoY) 7.70% -2.90% +10.60 XENE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.43% -2.43 OGN /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 6/9 -1.00 OGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.9 67.8 -22.86 OGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.10 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 29.0x 18.0x +11.00 OGN /forward-pe <GO>
Enterprise Scale & Market Cap $3.64B $3.63B $8.8M XENE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR XENE REV OGN REV XENE GROSS % OGN GROSS % XENE FCF OGN FCF
FY 2025 $0 $6.22B — 53.3% -$279.9M $538.0M
FY 2024 $0 $6.40B — 58.0% -$184.5M $764.0M
FY 2023 $0 $6.26B — — -$151.1M $799.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XENE // BETA 1.10
OGN // BETA —